The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2020 | BCL-2 frontline therapy in CLL
Michael Hallek, MD, University Hospital of Cologne, Cologne, Germany, explores why BCL-2 inhibition is a superior front-line treatment for patients with chronic lymphocytic leukemia (CLL) and highlights the benefit of combination therapy in CLL therapy, including agents such as venetoclax, obinutuzumab and ibrutinib for this indication. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
